FTDZX Fees and Costs — Franklin Biotechnology Discovery Fund, Advisor Class
Data updated: 2026-09-25
The net expense ratio is 0.76%: a 0.61% management fee plus 0.16% other expenses, less a 0.01% fee waiver. There are no sales loads or redemption fees. In fiscal 2026 the fund paid $734K in broker commissions, 0.0831% of average net assets, and portfolio turnover was 38%.
FTDZX Fees and Expenses
Annual operating expenses and sales charges of FTDZX. Prospectus, as of April 30, 2026.
| Annual operating expenses | |
|---|---|
| Management fee | 0.61% |
| 12b-1 fee | 0.00% |
| Other expenses | 0.16% |
| Gross expense ratio | 0.77% |
| Fee waiver | −0.01% |
| Net expense ratio | 0.76% |
| Sales charges | |
|---|---|
| Max front load | 0.00% |
| Max deferred load | 0.00% |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | Yes |
| Waived fees subject to recoupment | No |
FTDZX Costs Over Time
On $10,000 invested in FTDZX, assuming 5% a year before costs, total costs come to $529 over 5 years, cutting the return by 0.89% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 0.76%) | $80 | $249 | $433 |
| Trading costs (broker commissions) | $9 | $27 | $47 |
| Lost growth on money paid in costs | $0 | $14 | $48 |
| Total costs | $89 | $290 | $529 |
| Value after costs | $10,411 | $11,286 | $12,234 |
| Impact on return, per year | 0.89% | 0.89% | 0.89% |
FTDZX Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending April 30, 2026.
- Explicit cost rate (commissions ÷ average net assets): 0.0831%
- Total broker commissions: $734K
- Bought from dealers (principal trades, not a cost): $605.9M
- Portfolio turnover (prospectus): 38%
- Securities on loan, average value: $27.8M
- Net income from securities lending: $660K (0.075% of average net assets)
FTDZX Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| Instinet, LLC | $109K | 20.58% |
| Leerink Partners LLC | $68K | 12.93% |
| Wedbush Securities Inc. | $57K | 10.78% |
| Jefferies LLC | $56K | 10.62% |
| Guggenheim Securities, LLC | $54K | 10.29% |
| JonesTrading Institutional Services LLC | $48K | 9.04% |
| TD SECURITIES (USA) LLC | $45K | 8.43% |
| Oppenheimer & Co. Inc. | $35K | 6.54% |
| William Blair & Company, L.L.C. | $34K | 6.50% |
| Virtu Americas LLC | $23K | 4.29% |
FTDZX Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| J.P. Morgan Securities LLC | $524.7M | 87.29% |
| Jefferies LLC | $24.5M | 4.08% |
| Guggenheim Securities, LLC | $9.2M | 1.52% |
| Goldman Sachs & Co. LLC | $8.8M | 1.46% |
| Leerink Partners LLC | $7.4M | 1.24% |
| Merrill Lynch, Pierce, Fenner & Smith Inc. | $7.3M | 1.21% |
| Direct Investment India | $6.0M | 1.00% |
| TD SECURITIES (USA) LLC | $5.4M | 0.89% |
| Morgan Stanley & Co. LLC | $4.3M | 0.71% |
| Piper Sandler & Co. | $3.5M | 0.58% |
Franklin Biotechnology Discovery Fund Share Classes
Net expense ratio and maximum front-end load of each share class, cheapest first.
| Ticker | Class | Net expense ratio | Front load |
|---|---|---|---|
| FRBRX | Class R6 | 0.67% | none |
| FTDZX | Advisor Class | 0.76% | none |
| FBDIX | Class A | 1.01% | 5.50% |
| FBTDX | Class C | 1.76% | none |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.